Company intelligence / Profile preview

MIVI Neuroscience

Eden Prairie, Minnesota, United Statesmivineuro.com ↗

Ownership: Private
Development stage: Commercial

Overview

MIVI Neuroscience has developed the Q Revascularization System, a next-generation aspiration catheter system for mechanical thrombectomy in acute ischemic stroke. The pivotal EvaQ trial met its primary endpoint with 93.9% successful revascularization (mTICI 2b–3), supporting an FDA submission for US clearance. The system is already CE-marked and available internationally since 2018.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Cardeation Capital consortium investors including Philips, UPMC, American Heart AssociationPerceptive AdvisorsDeerfield Managementunnamed multinational medtech partner

Beyond the preview

Go deeper on MIVI Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIVI Neuroscience.

Explore the full profile